You are here

  • Home
  • Archive
  • Volume 73, Issue 1
  • A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients

Article metrics

Article menu
Basic and translational research
Extended report
A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients

 

Online download statistics by month:

Online download statistics by month: February 2013 to September 2024

AbstractFullPdf
Feb 20133023564
Mar 201325312692
Apr 20131988066
May 20131536362
Jun 20131364554
Jul 20131143320
Aug 2013982825
Sep 2013634216
Oct 2013502633
Nov 2013784652
Dec 201328457118
Jan 201410444114
Feb 20145435127
Mar 2014824452
Apr 2014674165
May 2014575173
Jun 2014695379
Jul 2014643239
Aug 2014373822
Sep 2014414639
Oct 2014524850
Nov 2014513127
Dec 2014425623
Jan 20155514627
Feb 2015434928
Mar 2015607934
Apr 20154111236
May 2015496436
Jun 2015279131
Jul 2015475919
Aug 2015437219
Sep 2015494328
Oct 2015172514
Nov 2015232519
Dec 2015334115
Jan 2016393326
Feb 2016262920
Mar 2016361824
Apr 2016473225
May 2016422522
Jun 2016361516
Jul 2016381823
Aug 2016332713
Sep 2016322926
Oct 2016372020
Nov 2016221714
Dec 2016312022
Jan 2017282011
Feb 2017143519
Mar 2017112213
Apr 2017153016
May 2017102923
Jun 2017133223
Jul 2017322623
Aug 2017494311
Sep 2017443616
Oct 2017534612
Nov 2017413515
Dec 2017484210
Jan 2018514314
Feb 2018393318
Mar 2018755720
Apr 2018443236
May 2018574426
Jun 2018454120
Jul 2018403718
Aug 2018483216
Sep 2018473516
Oct 2018403017
Nov 2018534517
Dec 2018443212
Jan 201936228
Feb 2019362617
Mar 2019544230
Apr 2019534720
May 2019302613
Jun 2019302337
Jul 2019433131
Aug 2019332919
Sep 2019252117
Oct 2019594518
Nov 2019373722
Dec 2019696612
Jan 2020544126
Feb 2020352921
Mar 2020474329
Apr 2020413921
May 2020272531
Jun 2020413135
Jul 202021198
Aug 2020473727
Sep 2020544921
Oct 2020524623
Nov 2020413925
Dec 2020483715
Jan 2021443613
Feb 2021352319
Mar 2021725518
Apr 2021524433
May 2021726936
Jun 2021595927
Jul 2021484826
Aug 2021302931
Sep 2021969455
Oct 2021545049
Nov 2021393936
Dec 2021494321
Jan 2022535624
Feb 2022585033
Mar 2022484626
Apr 2022544636
May 2022908741
Jun 2022756332
Jul 2022554528
Aug 2022524623
Sep 2022887384
Oct 2022687433
Nov 2022998838
Dec 2022393215
Jan 202325525235
Feb 202319718924
Mar 2023676227
Apr 2023685223
May 2023838027
Jun 2023836525
Jul 2023565114
Aug 2023545117
Sep 2023887813
Oct 202317916724
Nov 202325824830
Dec 2023737120
Jan 2024989827
Feb 2024926728
Mar 202411110298
Apr 20241167961
May 2024545231
Jun 2024675523
Jul 2024857824
Aug 2024635024
Sep 2024898232
Total897472204221